active: true
branding:
    icon_url: https://api.polygon.io/v1/reference/company-branding/bm92b25vcmRpc2suY29t/images/2025-04-04_icon.jpeg
    logo_url: https://api.polygon.io/v1/reference/company-branding/bm92b25vcmRpc2suY29t/images/2025-04-04_logo.svg
cik: 0000353278
composite_figi: BBG000BQBKR3
currency_name: usd
description: With roughly one-third of the global branded diabetes treatment market,
    Novo Nordisk is the leading provider of diabetes care products in the world. Based
    in Denmark, the company manufactures and markets a variety of human and modern
    insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic
    agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing
    less than 10% of revenue) that specializes in protein therapies for hemophilia
    and other disorders.
homepage_url: https://www.novonordisk.com
list_date: '1981-04-30'
locale: us
market: stocks
market_cap: 221193947391.2
name: Novo-Nordisk A/S
primary_exchange: XNYS
round_lot: 100
share_class_figi: BBG001S5TSK0
share_class_shares_outstanding: 3390128000
ticker: NVO
ticker_root: NVO
total_employees: 78387
type: ADRC
weighted_shares_outstanding: 4443430040
